Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Table 4

Details of multivariate analysis for overall survival.

Variable	Hazard ratio	value on Cox regression analysis
	>100 (0.0–NA)	0.980
ECOG PS	0.321 (0.078–1.322)	0.116
Smoking status	1.709 (0.475–6.153)	0.412
Brain metastasis	0.844 (0.176–4.042)	0.832
EGFR mutation type	0.361 (0.090–1.439)	0.149
Treatment received after failure on pemetrexed-carboplatin	0.265 (0.060–1.163)	0.078

was defined as age of 65 years or above. NA: not applicable.